Pfizer's 14% operational growth in non-COVID products shows the core business is stronger than many believe. The company's ...

Pfizer Inc. failed to warn patients that its injectable contraceptive drug Depo-Provera can increase the risk of developing ...

Pfizer has a well-diversified pipeline, with several late-stage assets to drive medium-term growth. Learn more about PFE ...

Raining on the parade even more, Pfizer just reported some good news that seems to confirm the presence of some internal issues. So let's examine this new green flag that's also a red flag for anyone ...

Pfizer (PFE) reported its third-quarter earnings on Tuesday, beating Wall Street expectations and its raising its full-year ...

Pfizer's newest anti-obesity program may disclose some of its early data soon. The company will also be getting some fresh ...

Pfizer has beaten analyst estimate both top- and bottom line. The firm has also raised its full-year guidance. Read my ...

Pfizer’s revenue from pharmaceuticals declined Pharmaceutical giant Pfizer is getting into the health care delivery business.

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Pfizer (PFE – Research Report) today. The company’s shares ...